Cowen & Co. initiated coverage on Entrada Therapeutics
$TRDA
Biotechnology: Pharmaceutical Preparations
Health Care
Cowen & Co. initiated coverage of Entrada Therapeutics with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2026 | $21.00 | Outperform | Oppenheimer |
| 12/6/2024 | $29.00 | Buy | ROTH MKM |
| 1/5/2024 | $22.00 | Outperform | Oppenheimer |
| 4/3/2023 | $25.00 | Buy | H.C. Wainwright |
| 11/24/2021 | Outperform | Evercore ISI Group | |
| 11/23/2021 | Outperform | Cowen & Co. | |
| 11/23/2021 | $29.00 | Neutral | Goldman Sachs |
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
EFFECT - Entrada Therapeutics, Inc. (0001689375) (Filer)
SCHEDULE 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, February 11, 2026, at 4:00 p.m. Eastern Time in New York, NY. TD Cowen 46th Annual Health Care Conference Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Tuesday, March 3, 2026, at 2:30 p.m. Eastern Time in Boston, MA. Live webcasts will be available on the Investor Relations section of the Company's website at www.entradatx.com. Replays will be available on the
-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit global regulatory applications for ENTR-601-51 in 2026 – -- Expands pipeline with selection of ENTR-801 as first clinical candidate in ocular diseases for the treatment of Usher syndrome type 2A and expects to nominate second clinical candidate in 2026 – -- Cash runway into Q3 2027 – -- Entrada to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET) -- BOSTON, Jan. 08, 2026
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET). A live webcast will be available on the Presentations portion of Entrada's Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event. About Entrada TherapeuticsEntrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage int
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4/A - Entrada Therapeutics, Inc. (0001689375) (Issuer)
Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $21.00
ROTH MKM initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $29.00
Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $22.00
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13D/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 -- -- Leadership team expanded with the additions of Navid Khan, PhD, as Senior Vice President of Medical Affairs and Kiran Patki, MD, MSc, FFPM, as Senior Vice President of Clinical Development -- -- Cash runway expected into Q2 2027 with $354 million in cash, cash equivalents and marketable securities as of June 30, 2025 -- BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) to
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada
āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,